{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vinorelbine+ditartrate", "query": { "intervention": "vinorelbine ditartrate" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 182, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vinorelbine+ditartrate&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T16:08:23.730Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02574455", "title": "Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Sacituzumab govitecan", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 529, "start_date": "2017-11-07", "completion_date": "2020-12-08", "has_results": true, "last_update_posted_date": "2022-06-15", "last_synced_at": "2026-09-27T16:08:23.730Z", "location_count": 185, "location_summary": "Daphne, Alabama • Mobile, Alabama • Phoenix, Arizona + 144 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02574455" }, { "nct_id": "NCT00477035", "title": "Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "CIK cells", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "bcnu", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sally Arai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 22, "start_date": "2006-05", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2017-01-11", "last_synced_at": "2026-09-27T16:08:23.730Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477035" }, { "nct_id": "NCT03414658", "title": "The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Utomilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adrienne G. Waks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2018-06-21", "completion_date": "2027-05-31", "has_results": true, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-27T16:08:23.730Z", "location_count": 17, "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414658" }, { "nct_id": "NCT00381940", "title": "Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Lymphocyte Depletion Hodgkin Lymphoma", "Adult Lymphocyte Predominant Hodgkin Lymphoma", "Adult Mixed Cellularity Hodgkin Lymphoma", "Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma", "Adult Nodular Sclerosis Hodgkin Lymphoma", "Childhood Lymphocyte Depletion Hodgkin Lymphoma", "Childhood Lymphocyte Predominant Hodgkin Lymphoma", "Childhood Mixed Cellularity Hodgkin Lymphoma", "Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma", "Childhood Nodular Sclerosis Hodgkin Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Stage I Adult Hodgkin Lymphoma", "Stage I Childhood Hodgkin Lymphoma", "Stage II Adult Hodgkin Lymphoma", "Stage II Childhood Hodgkin Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Childhood Hodgkin Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Childhood Hodgkin Lymphoma" ], "interventions": [ { "name": "ifosfamide", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "29 Years", "sex": "ALL", "summary": "Up to 29 Years" }, "enrollment_count": 26, "start_date": "2007-01", "completion_date": "2016-12-31", "has_results": true, "last_update_posted_date": "2021-03-24", "last_synced_at": "2026-09-27T16:08:23.730Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00381940" }, { "nct_id": "NCT06632327", "title": "Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Resectable Lung Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Surgical Procedure", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2024-12-11", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-27T16:08:23.730Z", "location_count": 415, "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 319 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06632327" }, { "nct_id": "NCT00151086", "title": "Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Estramustine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 33, "start_date": "2001-12", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2015-01-22", "last_synced_at": "2026-09-27T16:08:23.730Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00151086" }, { "nct_id": "NCT01416909", "title": "Managing Medication-induced Constipation in Cancer: A Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Constipation" ], "interventions": [ { "name": "Laxative Treatment", "type": "OTHER" }, { "name": "Standard of Care", "type": "OTHER" }, { "name": "Assessment Questionnaires", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 601, "start_date": "2008-11", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2017-02-23", "last_synced_at": "2026-09-27T16:08:23.730Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01416909" }, { "nct_id": "NCT00064077", "title": "Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma", "Recurrent Cervical Carcinoma", "Stage IVB Cervical Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Vinorelbine Tartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 513, "start_date": "2003-05", "completion_date": "2018-01-30", "has_results": true, "last_update_posted_date": "2018-10-17", "last_synced_at": "2026-09-27T16:08:23.730Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064077" }, { "nct_id": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "ER-positive Breast Cancer", "HER2-negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "AI+CDK4/6i", "type": "DRUG" }, { "name": "SERD+CDK4/6i", "type": "DRUG" }, { "name": "mTOR inhibitor + AI", "type": "DRUG" }, { "name": "mTOR inhibitor + SERD", "type": "DRUG" }, { "name": "mTOR inhibitor + Selective estrogen receptor modulator", "type": "DRUG" }, { "name": "PI3K inhibitor + SERD", "type": "DRUG" }, { "name": "PI3K inhibitor + AI", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Oral SERD", "type": "DRUG" }, { "name": "PARPi", "type": "DRUG" }, { "name": "AKT inhibitor", "type": "DRUG" }, { "name": "Step 3 Arm 2", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-06-12", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-09-27T16:08:23.730Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05826964" }, { "nct_id": "NCT00015938", "title": "S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 95, "start_date": "2001-05", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-09-27T16:08:23.730Z", "location_count": 99, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 61 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00015938" } ] }